We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00872885
Previous Study | Return to List | Next Study

Bunionectomy Trial With GRT6005

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00872885
Recruitment Status : Completed
First Posted : March 31, 2009
Last Update Posted : July 15, 2021
Information provided by (Responsible Party):
Tris Pharma, Inc.

Brief Summary:
The purpose of the trial is to determine whether the new centrally acting analgesic is effective in comparison to placebo and an active comparator (morphine).

Condition or disease Intervention/treatment Phase
Post Operative Pain Drug: GRT6005 Drug: Morphine Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 258 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Moderate to Severe Pain Following Bunionectomy.
Study Start Date : March 2009
Actual Primary Completion Date : August 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: A
Dose 1
Drug: GRT6005
liquid formulation, 200 to 600 µg, single dose, one day
Other Name: Morphine

Experimental: B
Dose 2
Drug: GRT6005
liquid formulation, 200 to 600 µg, single dose, one day
Other Name: Morphine

Experimental: C
Dose 3
Drug: GRT6005
liquid formulation, 200 to 600 µg, single dose, one day
Other Name: Morphine

Active Comparator: D
Drug: Morphine
60 mg

Placebo Comparator: E
Drug: Placebo
single dosage

Primary Outcome Measures :
  1. Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments [ Time Frame: 8 hours ]

Secondary Outcome Measures :
  1. Amount of rescue medication [ Time Frame: 24 hours ]
  2. Adverse events [ Time Frame: 24 hours ]
    Adverse Events reported by the participant as well as electrocardiogram, a measure of electrical activity of the heart and laboratory values

  3. Time to first rescue medication [ Time Frame: 24 hours ]
  4. Patient Global Impression of Change [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects scheduled to undergo primary unilateral first metatarsal bunionectomy

Exclusion Criteria:

  • Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound planned to be used during the anesthesia, or their excipients.
  • Concomitant inflammatory disease.
  • Life-long history of seizure disorder or epilepsy.
  • Subjects with impaired renal function
  • Subjects with impaired hepatic function
  • Female subjects who are pregnant or breastfeeding.
  • Resting pulse rate is <50bpm or >100 bpm after 5 minutes rest in supine position
  • resting blood pressure after 5 minutes rest in supine position: Systolic blood pressure is <100mmHg or >140 mmHg Diastolic blood pressure is <60 mmHg or > 90 mmHg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00872885

Layout table for location information
United States, Texas
Premier Research Group Ltd
Austin, Texas, United States, 78705
Sponsors and Collaborators
Tris Pharma, Inc.
Layout table for investigator information
Study Director: John Bothmer, Dr. Grünenthal GmbH
Layout table for additonal information
Responsible Party: Tris Pharma, Inc.
ClinicalTrials.gov Identifier: NCT00872885    
Other Study ID Numbers: 425965
KF5503/37 ( Other Identifier: Sponsor )
First Posted: March 31, 2009    Key Record Dates
Last Update Posted: July 15, 2021
Last Verified: July 2021
Keywords provided by Tris Pharma, Inc.:
post operative pain
single Hallux valgus repair
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents